MagForce AG / MagForce AG: Dr. Jan zur Hausen elected to the Supervisory Board of MagForce AG . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. * Renowned life sciences and investment banking expert strengthens the company's Supervisory Board Berlin, Germany, August 17, 2012 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, announced today that Dr. Jan zur Hausen was unanimously elected to the company's Supervisory Board at yesterday's Annual General Meeting. He is taking over from Dr. Stefan Eler, who resigned effective as of the end of the Annual General Meeting. Dr. Jan zur Hausen (born in 1965) is a managing shareholder of Bergmann zur Hausen & Cie. GmbH, a corporate finance company that evolved from Sal. Oppenheim's investment banking activities. While at Sal. Oppenheim, Dr. zur Hausen was responsible for numerous transactions in the life sciences area as Senior Vice President and Head of Healthcare. Dr. zur Hausen has in-depth knowledge of health sciences and investment banking. He has a degree in biology, gained a Ph.D. in cell biology from the University of Basel, and previously … Continue reading →

Berlin, Germany, August 17, 2012 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, announced today that Dr. Jan zur Hausen was unanimously elected to the company`s Supervisory Board at yesterday`s Annual General Meeting. He is taking over from Dr. Stefan Eler, who resigned effective as of the end of the Annual General Meeting. Dr. Jan zur Hausen (born in 1965) is a managing shareholder of Bergmann zur Hausen & Cie. GmbH, a corporate finance company that evolved from Sal. Oppenheim`s investment banking activities. While at Sal. Oppenheim, Dr. zur Hausen was responsible for numerous transactions in the life sciences area as Senior Vice President and Head of Healthcare. Dr. zur Hausen has in-depth knowledge of health sciences and investment banking. He has a degree in biology, gained a Ph.D. in cell biology from the University of Basel, and previously worked at Hoffmann-La Roche, MPM Capital, Mulligan BioCapital, and DVC Deutsche Venture Capital, among others. Dr. zur Hausen has known MagForce for many years now. "Dr. zur Hausen is an excellent addition to the Supervisory Board thanks to his many years` experience in the areas of both life sciences … Continue reading →

PRINCETON, N.J., Aug. 16, 2012 /PRNewswire/ --Nectid, Inc. (www.nectid.com), a Princeton based pharmaceutical product development company focused on discovering and developing novel drugs, announced initiating clinical development of agomelatine for autism and pain indications in the United States. Agomelatine is a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist and is approved for the treatment of major depressive disorder in Europe, Australia and in several countries. Agomelatine has been reported to resynchronize circadian rhythms to restore sleep cycle. Circadian rhythm is believed to be involved in several disorders such as neuropathic pain, fibromyalgia, inflammatory bowel disorders, autism spectrum disorders, and in multiple sclerosis. Nectid's founder/CEO Ram Sesha has said, "This is a repurposing program of a known drug to provide several key unmet needs. Sleep and fatigue are significant issues in chronic pain and multiple sclerosis, etc. Similarly, sleep difficulties particularly insomnia, occur in 5080% of children with autism spectrum disorders and tend to affect day time behavior. In our proof of concept studies, Agomelatine was found effective in reducing neuropathic pain, pain from fibromyalgia, and in improving sleep and day time behavior in children with Autism Spectrum Disorders. The data, to be released soon, was found statistically significant … Continue reading →

His wife, Maggie, had dropped him off at a doctor's appointment, and it was something about his hand. His cellphone kept slipping from his left hand. Later, a piece of paper was slipping, as well. He wasn't feeling well. "I remember walking downstairs going through the security there at the BOK, there was a young lady that I worked with," says Mellott, 63. "I said something to her, and suddenly my phone fell and it was all in parts." "She said, 'What's going on, Joe?' " Mellott recalls. If a stroke is real bad, he said, it comes on suddenly, and you know what it is. But if it's minor - like the Transient Ischemic Attack, or mini stroke, that Mellott had unbeknownst to him at some point in the past, recognizing it early and seeking treatment doesn't necessarily come as quickly. Early recognition is also difficult if the stroke comes on slowly, like Mellott's case that day in March. He said his speech was a bit slurred afterward and, more significantly, he'd lost a great deal of feeling on the left side of his body. Five months after the stroke, however, Mellott and his wife are in Tulsa on … Continue reading →

Study Highlights: EMBARGOED UNTIL 3 pm CT/4 pm ET, Thursday, August 16, 2012 DALLAS, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Black people who survived strokes caused by bleeding in the brain were more likely than whites to have high blood pressure a year later -- increasing their risk of another stroke, according to a study in the American Heart Association journal Stroke. The study examined racial and ethnic differences in these strokes, called intracranial hemorrhage or ICH. They account for only 10 percent of all strokes but have a death rate of about 40 percent in the first month, much higher than other types of stroke. High blood pressure is the most important modifiable risk factor associated with bleeding stroke. "If you have already had a stroke, blood pressure treatment can reduce your chance of having another stroke by between 25 and 50 percent," said Darin B. Zahuranec, M.D., M.S., lead author of the study and assistant professor of neurology at the University of Michigan Cardiovascular Center in Ann Arbor. However, more than half of patients in the study still had high blood pressure a year after the stroke, despite taking one or more anti-hypertensive medications. There were no significant … Continue reading →

THE public has come forward and generously donated to stroke victim Haramaini Mohd Idris to undergo treatment. In a little over a month, good Samaritans from all over the country including Kuala Lumpur, Selangor, Kedah, Negeri Sembilan and Penang, has helped raise a total of RM5,060 for the 59-year-old former political writer and campaign coordinator. However, the amount raised is insufficient. Haramaini needs another RM7,000 as up front payment of three months rental for a machine to undergo peritoneal dialysis. Ipoh Barat Barisian Nasional community service bureau chief Dr Cheng Wei Yee said the machine, which costs about RM4,000 to rent per month, would help Haramaini a lot. He currently relies on manual peritoneal dialysis, which has to be carried out five times a day. Each session takes about an hour and it is taking a toll on Haramainis poor state of health, Dr Cheng said after visiting Haramaini at his home in Pangsapuri Seri Kepayang in Ipoh. The frequent dialysis sessions means that Haramaini had no chance to leave home. His wife Pazian Shaharum, 57, said the manual process was stressful as it required Haramaini to shake his body continuously by moving the legs during each session to help … Continue reading →